Status:
UNKNOWN
Efficacy of Silymarin in Patients With Non-alcoholic Fatty Liver Disease - The SILIVER Trial
Lead Sponsor:
Camila Ribeiro de Avelar
Conditions:
Non-Alcoholic Fatty Liver Disease
Eligibility:
All Genders
20-60 years
Phase:
NA
Brief Summary
Non-Alcoholic Fatty Liver Disease (NAFLD) is one of the most prevalent chronic liver diseases in Brazil and its treatment is still limited. Thus, this project aims to conduct a double-blind, controlle...
Detailed Description
Non-Alcoholic Fatty Liver Disease (NAFLD) is one of the most prevalent chronic liver diseases in Brazil. It has a significantly increasing incidence today and is considered an important global health ...
Eligibility Criteria
Inclusion
- Adults between 20 and 60 years of age, both men and women,
- Clinical diagnosis of NAFLD, confirmed by imaging exams,
Exclusion
- Women in the menacing period, with the exception of those who have performed definitive sterilization, such as hysterectomy or tubal ligation.
- Patients with established prior diagnosis of chronic noncommunicable disease (congestive heart failure, decompensated or severe lung disease, neoplasms, renal disease, advanced liver disease - Child Pugh C classification)
- Patients with schistosomiasis;
- Hemochromatosis
- Wilson's disease
- Viral or autoimmune hepatitis
- HIV virus carriers
- Woman who is breastfeeding
- Users of illicit drugs
- Patients with an intake of more than 20 g / day of alcohol and / or past alcoholism with abstention less than 6 months;
- Patients with ingestion of medications such as steroids, estrogens, amiodarone, warfarin, anti-convulsants, antipsychotics, tamoxifen or other chemotherapeutic agents in the last 6 months
- Patients with clinically manifest infections or inflammation, surgery, trauma or hospitalization in the last 30 days
- Chronic non-hepatic degenerative diseases (sclerosis, Parkinson's disease or Alzheimer's disease)
- Patients who do not participate in all stages of the research.
Key Trial Info
Start Date :
February 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2022
Estimated Enrollment :
132 Patients enrolled
Trial Details
Trial ID
NCT03749070
Start Date
February 15 2019
End Date
August 31 2022
Last Update
August 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Camila Ribeiro de Avelar
Salvador, Estado de Bahia, Brazil, 40.110.060